Loading...
Citius Oncology, Inc.
CTOR•NASDAQ
HealthcareDrug Manufacturers - General
$0.89
$0.004(0.45%)
Citius Oncology, Inc. (CTOR) Stock Overview
Explore Citius Oncology, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.09
↓ 66.56%
EPS Growth
$-0.09
↑ 78.87%
Operating Margin
0.00%
↓ 69.72%
ROE
-14.85%
↓ 66.56%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
Price Targets
Low$0.00
Average$0.00
High$0.00
Company Profile
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
CEO
Mr. Leonard L. Mazur
Headquarters
420 Lexington Avenue, New York, NY
Founded
1970